Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Microbiotica Announces Completion of Recruitment in its International Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma | Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)

Cambridge, UK – 17 September 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its advanced melanoma (MELODY-1) trial.
This international trial has recruited 41 patients at clinical centres in the UK, France, Italy, and Spain. Initial results are expected in the first half of 2026.

Bridging the Capital Gap: New Report Calls for Investment in UK Research Commercialisation

A new research report, commissioned by Pioneer Group and The Crown Estate, has found that investing £15bn in UK university spinouts over the next 10 years could leverage a further £27bn of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, and boosting UK science on the global stage.

Authored by Henham Strategy, the report, titled: ‘Bridging the Capital Gap for UK Research Commercialisation,’ outlines the investment needed to translate the UK’s scientific excellence into global impact.

Coulter Partners successfully places Valerio Ferri as ExoLab Italia's new CEO

LONDON, UK, and MILAN, Italy, September 16, 2025 – Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Valerio Ferri as Chief Executive Officer (CEO) at ExoLab Italia.

ExoLab Italia is a biotech company producing plant-based exosomes for the cosmetics, nutraceutical, and pharmaceutical markets.

Comprehensive Range of Characterized Compounds and Libraries for Drug Discovery

Amsbio offers a wide selection of over 325,000 pre-characterized chemical compounds to support your drug screening applications for discovery and development.

From individual inhibitors, agonists and natural products to ready-to-screen compound libraries, these cost-effective, high-quality reagents are perfect for both academic and industrial research.

Medicines Discovery Catapult and Crown Bioscience Form Strategic Global Alliance for Radiopharmaceutical Innovation

The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.

Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals.

Graduate Technical Associate - IVD / Medical Devices

Graduate Technical Associate - IVD / Medical Devices

6 month contract, 2 vacancies, October 2025 start

Based in London

£ Highly competitive salary

Are you a Biomedical Engineering graduate, or an early career scientist / engineer with hands on experience within a Good Laboratory Practice (GLP) and/or Biosafety environment?

Would you like to join the team at a ground-breaking organisation to support the trial of their innovative molecular diagnostics platform?

Discovery Park’s Logical Biological Announces Strategic International Partnership for Engineered Disease State Materials

Sandwich, UK and Illkirch-Graffenstaden, France (10 September 2025) – Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.

Subscribe to